RET C634W

RET C634W被认为是激活髓系甲状腺癌RET的一种替代机制。虽然目前还没有RET特异性抑制剂，但混杂激酶抑制剂在治疗RET过度活性方面取得了一些成功。然而，数据表明，C634W突变可能导致耐药性，尤其是对血管内皮生长因子抑制剂莫特沙尼。
RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.